Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy
- PMID: 25179217
- PMCID: PMC4252738
- DOI: 10.1016/j.drugalcdep.2014.07.035
Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy
Abstract
Background: Sublingual formulations of buprenorphine (BUP) and BUP/naloxone have well-established pharmacokinetic and pharmacodynamic profiles, and are safe and effective for treating opioid use disorder. Since approvals of these formulations, their clinical use has increased. Yet, questions have arisen as to how BUP binding to mu-opioid receptors (μORs), the neurobiological target for this medication, relate to its clinical application. BUP produces dose- and time-related alterations of μOR availability but some clinicians express concern about whether doses higher than those needed to prevent opioid withdrawal symptoms are warranted, and policymakers consider limiting reimbursement for certain BUP dosing regimens.
Methods: We review scientific data concerning BUP-induced changes in μOR availability and their relationship to clinical efficacy.
Results: Withdrawal suppression appears to require ≤50% μOR availability, associated with BUP trough plasma concentrations ≥1 ng/mL; for most patients, this may require single daily BUP doses of 4 mg to defend against trough levels, or lower divided doses. Blockade of the reinforcing and subjective effects of typical doses of abused opioids require <20% μOR availability, associated with BUP trough plasma concentrations ≥3 ng/mL; for most individuals, this may require single daily BUP doses >16 mg, or lower divided doses. For individuals attempting to surmount this blockade with higher-than-usual doses of abused opioids, even larger BUP doses and <10% μOR availability would be required.
Conclusion: For these reasons, and given the complexities of studies on this issue and comorbid problems, we conclude that fixed, arbitrary limits on BUP doses in clinical care or limits on reimbursement for this care are unwarranted.
Keywords: Buprenorphine; Opioid dependence; Opioid receptors; Policy; Positron emission tomography; Treatment.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Conflict of interest statement
M.K.G. has received compensation as a scientific consultant to Reckitt-Benckiser Pharmaceuticals, Inc., which manufactures and markets buprenorphine products, and Titan Pharmaceuticals, Inc., which manufactures a buprenorphine product.
S.D.C. has received compensation (in the form of partial salary support) from investigator-initiated studies supported by Reckitt-Benckiser Pharmaceuticals, Inc. and Schering-Plough Corporation, companies that currently or previously market buprenorphine products. In addition, she received consulting income from Grunenthal GmbH and BioDelivery Sciences International, two companies that market buprenorphine products.
D.A.F. has received honoraria from Pinney Associates for serving on an external advisory board monitoring the abuse and diversion of buprenorphine.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4252738/bin/nihms625207f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4252738/bin/nihms625207f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4252738/bin/nihms625207f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4252738/bin/nihms625207f4.gif)
Similar articles
-
Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers.Neuropsychopharmacology. 2003 Nov;28(11):2000-9. doi: 10.1038/sj.npp.1300251. Neuropsychopharmacology. 2003. PMID: 12902992
-
Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices.Biol Psychiatry. 2007 Jan 1;61(1):101-10. doi: 10.1016/j.biopsych.2006.04.043. Epub 2006 Sep 1. Biol Psychiatry. 2007. PMID: 16950210 Clinical Trial.
-
Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data.Drug Dev Ind Pharm. 2020 Jan;46(1):1-7. doi: 10.1080/03639045.2019.1706552. Epub 2020 Jan 8. Drug Dev Ind Pharm. 2020. PMID: 31914818
-
Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.Adolesc Med State Art Rev. 2014 Aug;25(2):251-65. Adolesc Med State Art Rev. 2014. PMID: 27132312 Review. No abstract available.
-
Sublingual buprenorphine-naloxone precipitated withdrawal-A case report with review of literature and clinical considerations.Asian J Psychiatr. 2020 Oct;53:102121. doi: 10.1016/j.ajp.2020.102121. Epub 2020 May 16. Asian J Psychiatr. 2020. PMID: 32460142 Review.
Cited by
-
How Do I Manage Acute Pain for Patients Prescribed Buprenorphine for Opioid Use Disorder?NEJM Evid. 2024 May;3(5):EVIDccon2300275. doi: 10.1056/EVIDccon2300275. Epub 2024 Apr 23. NEJM Evid. 2024. PMID: 38815158 Review.
-
Neuraxial clonidine is not associated with lower post-cesarean opioid consumption or pain scores in parturients on chronic buprenorphine therapy: a retrospective cohort study.J Anesth. 2024 Jun;38(3):339-346. doi: 10.1007/s00540-024-03314-8. Epub 2024 Mar 10. J Anesth. 2024. PMID: 38461452
-
Relationship between opioid cross-tolerance during buprenorphine stabilization and return to opioid use during buprenorphine dose tapering.Psychopharmacology (Berl). 2024 Jun;241(6):1151-1160. doi: 10.1007/s00213-024-06549-1. Epub 2024 Feb 8. Psychopharmacology (Berl). 2024. PMID: 38326506 Clinical Trial.
-
Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder.Neuropsychopharmacology. 2024 May;49(6):1050-1057. doi: 10.1038/s41386-023-01793-z. Epub 2024 Jan 10. Neuropsychopharmacology. 2024. PMID: 38200140 Free PMC article.
-
Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.EClinicalMedicine. 2023 Nov 17;66:102311. doi: 10.1016/j.eclinm.2023.102311. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38045803 Free PMC article.
References
-
- Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am. J. Addict. 2004;13(Suppl. 1):S42–S66. - PMC - PubMed
-
- Amass L, Pukeleviciene V, Subata E, Almeida AR, Pieri MC, D’Egidio P, Stankova Z, Costa A, Smyth BP, Sakoman S, Wei Y, Strang J. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. Addiction. 2012;107:142–151. - PubMed
-
- Bertalmio AJ, Woods JH. Differentiation between mu and kappa receptor-mediated effects in opioid drug discrimination: apparent pA2 analysis. J. Pharmacol. Exp. Ther. 1987;243:591–597. - PubMed
-
- Bertalmio AJ, Woods JH. Reinforcing effect of alfentanil is mediated by mu opioid receptors: apparent pA2 analysis. J. Pharmacol. Exp. Ther. 1989;251:455–460. - PubMed
-
- Bickel WK, Amass L, Crean JP, Badger GJ. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology (Berl.) 1999;146:111–118. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials